Last reviewed · How we verify
MT-1303 High dose
At a glance
| Generic name | MT-1303 High dose |
|---|---|
| Sponsor | Tanabe Pharma Corporation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis (PHASE2)
- Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients (PHASE1)
- Dose-finding Study of MT-1303 (PHASE2)
- Extension Study of MT-1303 (PHASE2)
- A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303 (PHASE1)
- Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MT-1303 High dose CI brief — competitive landscape report
- MT-1303 High dose updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI